Tenderwize
Wróć do wyszukiwania

Open House Originale Agreement for Tacrolimus (Retard Tablets)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 278 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-15 - Tacrolimus (Retardtabletten)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice contains multiple end-date representations (structured data, XML notice, and timezone variants). This create...

Eligibility is restricted to pharmaceutical manufacturers with the required seat, authorisation, and reliability declar...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products, specifically Tacrolimus (retard tablets).
  • Open House original rebate agreements under Section 130c(1) SGB V.
Pokaż pełne podsumowanie

Open House supply arrangement for Tacrolimus (retard tablets) in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical manufacturer may join during the contract period, but only if it meets the stated legal and reliability conditions and provides the required self-declarations. No contract value is stated. Electronic submission via the portal is not allowed; contracts must be submitted by email with qualified electronic signature or by post, and the procurement documents are available electronically but were not analyzed in extracted text beyond the notice XML.

Ryzyka

The notice contains multiple end-date representations (structured data, XML notice, and timezone variants). This create...

Eligibility is restricted to pharmaceutical manufacturers with the required seat, authorisation, and reliability declar...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical manufacturer within the meaning of Section 4(18) AMG for the relevant medicinal product.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant product and/or otherwise be entitled to place it on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Originale Agreement for Tacrolimus (Retard Tablets)

Supply arrangement for Tacrolimus (retard tablets) under an Open House procedure. Scope is nationwide in Germany. The lot information comes from structured data and XML notice. No lot value is stated. The contract can be joined at any time during the contract period, subject to eligibility and document requirements.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

May 2025 - May 2027

Kategoria

Pharmaceutical products

Termin

Deadline May 30, 2027

Szczegóły zamówienia

Data publikacji
21 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
260054-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3